Charting the Future of Medtech
MedTech is no longer just a future opportunity...
It is a current growth engine for Singapore’s PE sector.
At our recent SPETA x MedTech Catapult session, participants explored how local manufacturers can successfully enter and scale within the MedTech space.
From regulatory compliance to design for manufacturability, the session unpacked challenges and considerations that come with breaking into MedTech. Companies shared their experiences around achieving certification, building cleanrooms, and deciding when to bring production in-house versus outsourcing. These are critical decisions that shape long-term competitiveness and credibility.
We also explored how Singapore’s well-connected trade infrastructure, strong innovation ecosystem, and access to regional markets support MedTech startups and manufacturers from prototype to commercial production.
The role of partnerships stood out strongly, collaborations between contract manufacturers, product innovators, and research institutions are essential to accelerate innovation and reduce risk.
Equally important was the conversation around talent and capability gaps.
As the MedTech manufacturing sector expands, so too does the need for professionals who understand the unique requirements of regulated industries — from quality assurance to biomedical engineering. Support is available, but awareness and early planning are key.
The takeaway from the session was clear. There is meaningful space for SMEs in MedTech, but success requires strategic investment, business commitment, regulatory readiness, and the right ecosystem partners.
Thank you to Justin Phoon, Daniel W., @Zheng Yiying / MedTech Catapult, Khoon Seng Goh/Osteopore and to all who joined the session.
SPETA looks forward to continuing the momentum and helping more local manufacturers to level up their involvement in Medtech and also help others to progressively be part of the community!